Determining the length of posttherapeutic follow-up for cancer patients using competing risks modeling.

about

Determining the length of posttherapeutic follow-up for cancer patients using competing risks modeling.

Item

http://www.wikidata.org/entity/Q45168012

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Determining the length of post ...... sing competing risks modeling.

@en

Determining the length of post ...... sing competing risks modeling.

@nl

type

Item

label

Determining the length of post ...... sing competing risks modeling.

@en

Determining the length of post ...... sing competing risks modeling.

@nl

prefLabel

Determining the length of post ...... sing competing risks modeling.

@en

Determining the length of post ...... sing competing risks modeling.

@nl

P1476

Determining the length of post ...... sing competing risks modeling.

@en

P2093

Andrew Kramar

http://www.w3.org/2001/XMLSchema#string

Christine Chevreau

http://www.w3.org/2001/XMLSchema#string

Eve Leconte

http://www.w3.org/2001/XMLSchema#string

Maria Rios

http://www.w3.org/2001/XMLSchema#string

Martine Delannes

http://www.w3.org/2001/XMLSchema#string

Serge M A Somda

http://www.w3.org/2001/XMLSchema#string

P2860

Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database

Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry.

The follow-up of adult soft-tissue sarcomas.

Surveillance strategies for patients following surgical resection of soft tissue sarcomas.

Competing risks determining event-free survival in early breast cancer.

Follow up after Primary Treatment of Soft Tissue Sarcoma: A Survey of Current Practice in the United Kingdom.

Evaluation of nonlinear optimization for scheduling of follow-up cystoscopies to detect recurrent bladder cancer. The Bladder Cancer follow-up Group.

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Regression models for relative survival.

Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis.

P304

168-179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0272989X13492015

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Filleron

Nicolas Penel

P577

2013-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23811759

http://www.w3.org/2001/XMLSchema#string